---
id: ESBL-Enterobacterales_071
category: organisms
tags: [ESBL, extended-spectrum-beta-lactamase, Enterobacterales, carbapenem, cefepime-enmetazobactam]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## ESBL-Producing Enterobacterales

**Q:** What are the treatment options and controversies for ESBL-producing Enterobacterales infections, including new carbapenem-sparing agents?

**A:**

**Definition:**
- **Extended-Spectrum β-Lactamase (ESBL):** Enzymes that hydrolyze penicillins, cephalosporins (including 3rd/4th generation), and aztreonam
- **DO NOT hydrolyze carbapenems** (remain susceptible)
- Most common: CTX-M, SHV, TEM types

**Organisms:**
- **E. coli** (most common)
- **Klebsiella pneumoniae**
- Other Enterobacterales (Proteus, Enterobacter, etc.)

---

**Epidemiology & Risk Factors:**

**Patient Risk Factors:**
- Antibiotic exposure (fluoroquinolones, 3rd-generation cephalosporins)
- Prolonged hospitalization
- ICU stay
- Indwelling catheters (urinary, vascular)
- Recent healthcare exposure (nursing home, dialysis)
- International travel (South Asia, Middle East)
- Prior ESBL colonization/infection

**Global Distribution:**
- **Highest prevalence:** South Asia (India: 70-80%), Middle East, Eastern Europe
- **US:** 5-10% of E. coli, 10-20% of K. pneumoniae

---

**Clinical Syndromes:**

**1. Urinary Tract Infection (Most Common):**
- Cystitis, pyelonephritis, catheter-associated UTI
- Community-acquired or healthcare-associated

**2. Bloodstream Infection:**
- Often from urinary source
- Mortality: 20-40% (if inappropriate empiric therapy)

**3. Intra-Abdominal Infection:**
- Biliary tract infection
- Peritonitis
- Intra-abdominal abscess

**4. Pneumonia:**
- Hospital-acquired pneumonia
- VAP

---

**Treatment:**

**Key Principle:** **Carbapenems preferred** for invasive ESBL infections (IDSA 2024)

---

**1. First-Line: Carbapenems**

**IDSA 2024 Guidance:**
- **Carbapenems** = preferred treatment for ESBL bloodstream infections

**Carbapenem Options:**

| **Agent** | **Dosing** | **Notes** |
|-----------|------------|-----------|
| **Ertapenem** | 1g IV q24h | **Preferred** (once daily, narrow spectrum)<br>**Limitations:** Not for critically ill, low albumin, Pseudomonas |
| **Meropenem** | 1g IV q8h | For critically ill, Pseudomonas coverage |
| **Imipenem-cilastatin** | 500 mg IV q6h or 1g IV q8h | Alternative |

**Why Carbapenems?**
- **100% susceptible** (ESBLs do NOT hydrolyze carbapenems)
- **Superior outcomes** in RCTs for bloodstream infections
- **Lower mortality** compared to piperacillin-tazobactam in meta-analyses (historical)

---

**2. Non-Carbapenem Options (Carbapenem-Sparing):**

**A. Piperacillin-Tazobactam (Controversial):**

**Historical Position:**
- **NOT recommended** for invasive ESBL infections (IDSA guidance)
- In vitro susceptibility does NOT correlate with clinical success
- Higher mortality in early RCTs

**2024 Updated Evidence:**
- **Recent meta-analyses:** Piperacillin-tazobactam **non-inferior** to carbapenems for ESBL bloodstream infections (30-day mortality difference <5%)
- **Conditions for consideration:**
  - MIC ≤8 μg/mL (susceptible)
  - Not critically ill
  - Source control achieved
  - Close monitoring

**IDSA 2024 Stance:** Still suggests carbapenems preferred, but acknowledges evolving evidence

**B. Cefepime:**

**Very Limited Role:**
- **Uncomplicated cystitis ONLY** (if empirically started and clinical improvement occurs)
- **NOT for pyelonephritis, cUTI, or invasive infections** (IDSA 2024)
- High risk of clinical failure

**C. Cefepime-Enmetazobactam (NEW - FDA Approved February 2024):**

**Mechanism:**
- **Enmetazobactam:** Novel β-lactamase inhibitor (inhibits ESBLs)
- Restores cefepime activity

**Efficacy:**
- **Phase 3 trial (ALLIUM):** **Cefepime-enmetazobactam superior to piperacillin-tazobactam** for complicated UTI
- **Effective carbapenem-sparing option**

**Dosing:**
- **Cefepime-enmetazobactam:** 2g/2g IV q8h

**Indications:**
- Complicated UTI (cUTI)
- Acute pyelonephritis
- ESBL-producing Enterobacterales

**Advantage:**
- **Carbapenem-sparing** (preserve carbapenems for CRE)

**D. Temocillin (Not Available in US):**
- Narrow-spectrum penicillin
- Active against ESBLs
- Used in Europe

---

**3. Treatment by Syndrome:**

**Uncomplicated Cystitis (ESBL):**
- **First-line:** **Nitrofurantoin** 100 mg PO BID x 5 days (if susceptible)
- **Alternatives:** **Fosfomycin** 3g PO x1, TMP-SMX (if susceptible and local resistance <20%)
- **If treatment failure:** Consider **ertapenem** 1g IV q24h x 3 days (outpatient option)

**Pyelonephritis / cUTI (ESBL):**
- **Preferred:** **Ertapenem** 1g IV q24h x 5-14 days
- **Alternative:** **Cefepime-enmetazobactam** 2g/2g IV q8h (new option)
- **Avoid:** Cefepime monotherapy, piperacillin-tazobactam (unless non-severe + close monitoring)

**Bloodstream Infection (ESBL):**
- **Preferred:** **Carbapenem** (ertapenem 1g q24h OR meropenem 1g q8h)
- Duration: 7-14 days (depends on source control, clinical response)
- **Controversial:** Piperacillin-tazobactam IF MIC ≤8, not critically ill (2024 evolving evidence)

**Intra-Abdominal Infection (ESBL):**
- **Preferred:** **Carbapenem** (ertapenem or meropenem) + source control (drainage/surgery)
- Duration: 4-7 days (after source control)

**Pneumonia (ESBL):**
- **Preferred:** **Meropenem** 1g IV q8h (not ertapenem - poor lung penetration)
- Duration: 7 days (uncomplicated)

---

**4. Step-Down Therapy:**

**After Clinical Improvement:**
- Switch to **oral** agent (if susceptible):
  - **Ciprofloxacin** 500-750 mg PO BID (if susceptible)
  - **TMP-SMX** DS 1 tab PO BID (if susceptible)
  - **Nitrofurantoin** (for UTI only)

**Total Duration:**
- **UTI:** 5-14 days
- **Bacteremia:** 7-14 days
- **Intra-abdominal:** 4-7 days (post-source control)

---

**Resistance Patterns:**

**Typical ESBL Resistance Profile:**
- ✅ **Susceptible:** Carbapenems (100%), aminoglycosides (variable), fluoroquinolones (variable - often resistant)
- ❌ **Resistant:** Penicillins, cephalosporins (3rd/4th gen), aztreonam

**Co-Resistance:**
- **Fluoroquinolones:** 60-80% co-resistance (common)
- **Aminoglycosides:** 30-50% co-resistance
- **TMP-SMX:** 50-70% co-resistance

---

**Carbapenem Stewardship:**

**Why Limit Carbapenem Use?**
- **Carbapenem overuse** → ↑ CRE (carbapenem-resistant Enterobacterales)
- **Ecological pressure** (Stenotrophomonas, CRAB, Candida, C. difficile)

**Carbapenem-Sparing Strategies:**
- **Nitrofurantoin, fosfomycin** for uncomplicated ESBL UTI
- **Cefepime-enmetazobactam** for cUTI/pyelonephritis (FDA 2024)
- **Piperacillin-tazobactam** for select ESBL bacteremia (if MIC ≤8, not critically ill - controversial)

---

**Comparison: ESBL vs CRE**

| **Feature** | **ESBL** | **CRE** |
|-------------|----------|---------|
| **β-lactamase** | ESBL (CTX-M, SHV, TEM) | Carbapenemase (KPC, NDM, OXA-48) |
| **Carbapenem susceptibility** | ✅ **Susceptible** | ❌ **Resistant** |
| **First-line Rx** | **Carbapenem** (ertapenem) | CAZ-AVI, M-V, I-R (depends on mechanism) |
| **Mortality** | 20-40% (BSI, if inappropriate Rx) | 40-60% (BSI) |
| **Prevalence (US)** | 5-20% | 1-5% |

---

**Mnemonic: "ESBL = Ertapenem is Superior for Bloodstream Infections (but Looking at alternatives)"**
- **E**rtapenem preferred (carbapenems first-line)
- **S**usceptible to carbapenems (100%)
- **B**loodstream infections (20-40% mortality if inappropriate Rx)
- **L**ooking at alternatives (cefepime-enmetazobactam, piperacillin-tazobactam controversial)

**Mnemonic: "Carbapenem-Sparing = FUN"**
- **F**osfomycin (uncomplicated UTI)
- **U**ncomplicated cystitis → nitrofurantoin
- **N**ew agent: Cefepime-enmetazobactam (FDA 2024)

**Clinical Pearls:**
- **Carbapenems = gold standard** for ESBL bloodstream infections (IDSA 2024)
- **Ertapenem preferred** (once daily, narrow spectrum) - but NOT for critically ill, Pseudomonas, or low albumin
- **Piperacillin-tazobactam controversial** (2024 meta-analyses show non-inferiority, but IDSA still prefers carbapenems)
- **Cefepime monotherapy:** Only for uncomplicated cystitis (NOT pyelonephritis or invasive)
- **Cefepime-enmetazobactam (FDA February 2024):** Effective carbapenem-sparing option for cUTI/pyelonephritis
- **Nitrofurantoin/fosfomycin excellent** for uncomplicated ESBL cystitis (avoid carbapenems)
- **Co-resistance common:** 60-80% fluoroquinolone resistance, 50-70% TMP-SMX resistance
- **Carbapenem stewardship important:** Overuse → CRE
- **Step down to PO** after improvement (ciprofloxacin, TMP-SMX if susceptible)
- **Source control essential** (drain abscesses, remove catheters)

**Media:** None

**Sources:** [IDSA 2024 - AMR guidance], [OUP 2023 - REDUCE-UTI cefepime/piperacillin-tazobactam], [ScienceDirect 2024 - Pip-tazo vs carbapenems meta-analysis], [PubMed 2025 - Pip-tazo vs carbapenems non-inferiority], [Taylor & Francis 2025 - Cefepime-enmetazobactam first approval], [PMC 2025 - Cefepime-enmetazobactam for MDR Enterobacterales]
